☆ 4.7 Article

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

DRUG DELIVERY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Evaluation of favipiravir in the treatment of COVID-19 based on the real-world

Weishang Deng et al.

Summary: For mild-to-moderate COVID-19 patients, FVP significantly promotes viral clearance, reduces hospitalization duration, and helps lower the risk of severe disease outcomes. However, there is no significant benefit of FVP for severe patients, indicating caution is needed in treatment options.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

添加到收藏夹

Editorial Material Immunology

Future of antivirals in COVID-19: The case of favipiravir

Chia Siang Kow et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

添加到收藏夹

Article Chemistry, Analytical

A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling

Hoda M. Marzouk et al.

Summary: A stabilityindicating HPLC-DAD method was developed and validated for determination of favipiravir under different stress conditions, showing its susceptibility to acid, base hydrolysis, and oxidative degradation. Mass spectrometry was used for structure elucidation of forced degradation products, and effective separation of FAV and its degradation products was achieved on a Zorbax C18 column. The proposed method proved to be accurate, reliable, time-saving, and cost-effective for regular quality control and stability assessment of FAV in tablet form.

MICROCHEMICAL JOURNAL (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies

Serdar Durdagi et al.

Summary: This study identified montelukast as a novel agent that has dual potential in inhibiting SARS-CoV-2 by targeting both the main protease enzyme and virus entry into host cells. In vitro experiments demonstrated a delayed activity of SARS-CoV-2 virus with the use of montelukast for 20 hours on infected cells.

MOLECULAR THERAPY (2022)

添加到收藏夹

Article Biochemical Research Methods

Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method

Divya Kumar Vemuri et al.

Summary: The developed HPLC method is specific and accurate for the determination of degradation impurities in favipiravir film-coated tablets, with good recovery rates and linearity. The method is suitable for routine analysis and quality control in the research and development process.

BIOMEDICAL CHROMATOGRAPHY (2022)

添加到收藏夹

Article Immunology

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

Neslihan Pakize Tasli et al.

Summary: The COVID-19 pandemic has prompted the development of new therapeutics, including the use of convalescent plasma and convalescent plasma-derived exosomes. In this study, the authors present a comprehensive characterization of their proprietary product, convalescent human immune plasma-derived exosome, which shows promising safety and efficacy against SARS-CoV-2 infections in preclinical models.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development

Yuefei Zhu et al.

Summary: The global outbreak of COVID-19 has posed a serious threat to humanity, requiring a more in-depth understanding of the epidemic and the development of rational containment strategies. While there is currently no specific antiviral therapy, rapid detection technology and promising treatment methods have been helpful.

ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Review Infectious Diseases

Role of favipiravir in the treatment of COVID-19

Shashank Joshi et al.

Summary: Favipiravir has shown promising results in clinical studies worldwide, demonstrating potential efficacy against COVID-19, and is being included in treatment protocols by multiple countries.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Causes of death and comorbidities in hospitalized patients with COVID-19

Sefer Elezkurtaj et al.

Summary: The study conducted autopsies on 26 patients who died after SARS-CoV-2 infection and COVID-19, finding that septic shock and multi organ failure were the most common immediate causes of death, often due to suppurative pulmonary infection. Most patients had comorbidities such as hypertension, ischemic heart disease, and obesity. The majority of deaths were found to be directly related to COVID-19, with contributory implications of preexisting health conditions to the mechanism of death.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis

Ahmad Alamer et al.

Summary: The study found that Favipiravir was associated with clinical benefits in COVID-19 patients, including accelerated discharge rate and less progression to mechanical ventilation. However, no overall mortality benefits were seen across the severity spectrum. Age was identified as an independent risk factor for mortality in mechanically ventilated patients.

CURRENT MEDICAL RESEARCH AND OPINION (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial

Mustafa Erelel et al.

Summary: Administering low-molecular-weight heparin via a soft-mist inhaler has shown significant improvement in treating acute respiratory distress syndrome in COVID-19 patients, particularly in cases of severe hypoxemia.

PHARMACEUTICS (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

Zainab Almoosa et al.

Summary: The study found that treating COVID-19 patients with Favipiravir did not lead to improvements in clinical outcomes or mortality. While early day 14 mortality was slightly reduced, day 28 mortality increased, and overall mortality was slightly higher in the Favipiravir group compared to the standard of care, although the difference was not statistically significant.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)

添加到收藏夹

Article Chemistry, Medicinal

Favipiravir and COVID-19: A Simplified Summary

Morteza Ghasemnejad-Berenji et al.

Summary: This review summarizes the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19, highlighting it as a potential treatment option for the novel coronavirus infection.

DRUG RESEARCH (2021)

添加到收藏夹

Letter Cell Biology

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Manli Wang et al.

CELL RESEARCH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Kimiyasu Shiraki et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Microbiology

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Sangeun Jeon et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Letter Pharmacology & Pharmacy

Lung tissue distribution of drugs as a key factor for COVID-19 treatment

Yan Wang et al.

BRITISH JOURNAL OF PHARMACOLOGY (2020)

添加到收藏夹

Letter Medicine, General & Internal

Transmission of coronavirus by nebulizer: a serious, underappreciated risk

Israel Amirav et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Du Yin-Xiao et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

In Vitro and Animal Models for SARS-CoV-2 research

Kazuo Takayama

TRENDS IN PHARMACOLOGICAL SCIENCES (2020)

添加到收藏夹

Letter Biochemistry & Molecular Biology

The proximal origin of SARS-CoV-2

Kristian G. Andersen et al.

NATURE MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review

W. Joost Wiersinga et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Identifying airborne transmission as the dominant route for the spread of COVID-19

Renyi Zhang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Promoting safe and effective use of aerosol devices in COVID-19: risks and suggestions for viral transmission

Arzu Ari

EXPERT OPINION ON DRUG DELIVERY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Ashleigh Shannon et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Respiratory System

Lung Deposition Using the Respimat(R) Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An In Vitro/In Silico Analysis

Anna-Maria Ciciliani et al.

COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2020)

添加到收藏夹

Article Biochemical Research Methods

Robust real-time cell analysis method for determining viral infectious titers during development of a viral vaccine production process

Cedric Charretier et al.

JOURNAL OF VIROLOGICAL METHODS (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Yousuke Furuta et al.

PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)

添加到收藏夹

Article Respiratory System

Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique

Anja Schulze

International Journal of Chronic Obstructive Pulmonary Disease (2016)

添加到收藏夹

Article Critical Care Medicine

Evaluation of 36 formulas for calculating plasma osmolality

Andreas S. Fazekas et al.

INTENSIVE CARE MEDICINE (2013)

添加到收藏夹

Article Biochemical Research Methods

Real-time cell analysis - A new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity

Zheng Teng et al.

JOURNAL OF VIROLOGICAL METHODS (2013)

添加到收藏夹

Article Biochemical Research Methods

Real-time monitoring of flavivirus induced cytopathogenesis using cell electric impedance technology

Ying Fang et al.

JOURNAL OF VIROLOGICAL METHODS (2011)

添加到收藏夹

Review Pharmacology & Pharmacy

Formulation strategy and use of excipients in pulmonary drug delivery

Gabrielle Pilcer et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mechanisms of acid and base secretion by the airway epithelium

Horst Fischer et al.

JOURNAL OF MEMBRANE BIOLOGY (2006)

添加到收藏夹

Article Public, Environmental & Occupational Health

Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler

G Pitcairn et al.

JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG (2005)

添加到收藏夹

Article Chemistry, Multidisciplinary

Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans

GN Kumar et al.

PHARMACEUTICAL RESEARCH (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.